PTPRC and neoplasm: Consistent with our previous findings that Roscovitine decreases PD-L1 levels in tumor cells (12), treatment with Roscovitine significantly decreased the PD-L1-associated MFI in tumor-derived CD45- populations, which consist primarily of tumor cells devoid of immune cells (Figure 4J).